Loading viewer...
earnings
Format: PDF earnings
Ambu reported solid FY2024/25 results with 13.1% total growth and 15.4% endoscopy growth, driven by continued conversion from reusable to single-use endoscopy. EBIT margin improved to 13.0%, supported by operating leverage and commercial investment. The company launched its ZOOM AHEAD strategy targeting global endoscopy leadership with extended long-term financial targets through FY2029/30.
investor_presentation
13 Pages
earnings
21 Pages
Inogen, Inc.
Coca-Cola Q2 2023 Investor Overview Presentation
earningsearnings
43 Pages
The Coca-Cola Company